Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial-Reference-Cited by-同舟云学术

Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial

Published:2015-07 Issue:32 Volume:33 Page:3940-3946
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Wu Ting,Hu Yue-Mei,Li Juan,Chu Kai,Huang Shou-Jie,Zhao Hui,Wang Zhong-Ze,Yang Chang-Lin,Jiang Han-Min,Wang Yi-Jun,Lin Zhi-Jie,Pan Hui-Rong,Sheng Wei,Wei Fei-Xue,Li Shao-Wei,Wang Ying,Zhu Feng-Cai,Li Chang-Gui,Zhang Jun,Xia Ning-Shao

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference25 articles.

1. ICO Information Centre on HPV and Cancer (HPV Information Centre). Human papillomavirus and related diseases in the world;Bruni,2015

2. Human papillomavirus vaccines: WHO position paper, October 2014—Recommendations. Vaccine, 2014, http://dx.doi.org/10.1016/j.vaccine.2014.12.002

3. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions;Group;N Engl J Med,2007

4. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases;Garland;N Engl J Med,2007

5. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial;Paavonen;Lancet,2007

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vaccination with a Human Papillomavirus L2 Multimer Provides Broad Protection against 17 Human Papillomavirus Types in the Mouse Cervicovaginal Challenge Model;Vaccines;2024-06-20

2. Study on the Knowledge of Mothers or Guardians of Girls Aged 9 - 14 from the Langue de Barbarie in Saint-Louis, Senegal about Cervical Cancer and Its Relationship to HPV Vaccination in 2024;Journal of Immune Based Therapies, Vaccines and Antimicrobials;2024

3. Safety and immunogenicity of a pichia pastoris-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine in healthy Chinese women aged 9–45 years: A randomized, double-blind, placebo-controlled phase 1 clinical trial;Vaccine;2023-05

4. Efficacy, immunogenicity and safety of HPV vaccination in Chinese population: A meta-analysis;Frontiers in Public Health;2023-02-17

5. Sleep quality was associated with adverse reactions after coronavirus disease 2019 vaccination among healthcare workers: A longitudinal paired study;Frontiers in Behavioral Neuroscience;2023-01-04